Celerion’s Post

iPSC Scientists/Researchers in Cardiac Discovery or Safety Tox! We've collated our expertise, capabilities and iPSC products into our 2024 Cardiac Guide, which includes information on: • The growing need for better cardiotoxicity models • Data behind our high-quality axoCells™ ventricular and atrial cardiomyocytes • How we can support cardiac research with custom axoServices™ projects • Concepts on the horizon to improve in vitro cardiotoxicity models • Examples of our work in the cardiac space, including CiPA validation and chamber-specific pharmacology experiments Click here to download our 2024 Cardiac Guide: https://hubs.la/Q02w7Bwc0 If you'd like to discuss a project, please get in contact at operations@axolbio.com #cellculture #organoids #research #cardiacdisease #pharma #biotech #mps #humancells #ipsc

A comprehensive solution for in vitro cardiac safety assessment and cardiovascular drug discovery. Agilent offers two instruments for assessment, drug discovery, screening, and the evaluation of cardiomyocyte models: – The Agilent xCELLigence RTCA Cardio, which measures viability and contractility. – The Agilent xCELLigence RTCA CardioECR, which measures viability and contractility, with the added benefit of ion channel activity and functional maturation of cardiomyocytes. This groundbreaking instrument integrates high-frequency impedance measurement with multi-electrode array technology, providing unparalleled insights into cardiomyocyte contractility, viability, and electrophysiology. With the added benefit of electronic pacing, it functionally matures hiPSC cardiomyocytes, enhancing cell models for drug discovery, safety/tox assessment, and cardiac disease research. Discover how xCELLigence RTCA CardioECR is revolutionizing the assessment of cardiomyocyte health and driving innovative cardiac research. Reach out to us at marketing@medispec.in or 77188 10037 to learn more! #CardiacResearch #DrugDiscovery #Cardiotoxicity #realtimecellanalysis #medispec

Working with in vitro cardiotoxicity models? Looking for functional atrial cardiomyocytes for arrhythmia models? We can help! We've pulled together everything you need to know about our axoCells™ Atrial Cardiomyocytes including: ·      Key features and applications including cardiac safety pharmacology and modeling AF and other arrhythmias ·      Data behind the phenotypic characterization and functional relevance of our atrial cardiomyocytes, including chamber-specific pharmacological responses ·      Essential ordering information and user protocols Take a look at the graphic to see the atrial cardiomyocyte chapter of our axoCells Catalog, and click here to download the full thing: https://lnkd.in/epUnnZWt If you'd like to learn more about our work with iPSC-derived ventricular and atrial cardiomyocytes, click here to explore our 2024 Cardiac Guide: https://lnkd.in/eWWWV_-s #iPSCs #AtrialCardiomyocytes #AtrialFibrillation #cardiotoxicity #StemCells

🚨 Clinical Trial Recruitment: "Study of Cryoablation and Nirogacestat for Desmoid Tumor" Stanford University recently opened up a new clinical trial for desmoid tumors combining local treatment of cryoablation with the newly FDA approved gamma secretase inhibitor, nirogacestat (OGSIVEO). The ideal candidates for this trial are patients with desmoid tumors that cannot be completely cryoablated, with a target of 50-75% of the tumor volume for cryoablation. Currently recruiting patients who have US medical insurance and are able to travel to Stanford monthly for treatment. All patients must have the MRIs evaluated by Stanford interventional radiologists to determine if they are suitable for trial enrollment. View the trial details and criteria: https://lnkd.in/e3FJqrg2 #Desmoid #clinicaltrial #DesmoidTumors #DesmoidTumor #aggressivefibromatosis #DTRF #DesmoidTumorResearchFoundation #Desmoidian #desmoidresearch

Working with in vitro cardiotoxicity models? Looking for functional atrial cardiomyocytes for arrhythmia models? We can help! We've pulled together everything you need to know about our axoCells™ Atrial Cardiomyocytes including: ·      Key features and applications including cardiac safety pharmacology and modeling AF and other arrhythmias ·      Data behind the phenotypic characterization and functional relevance of our atrial cardiomyocytes, including chamber-specific pharmacological responses ·      Essential ordering information and user protocols Take a look at the graphic to see the atrial cardiomyocyte chapter of our axoCells Catalog, and click here to download the full thing: https://lnkd.in/epUnnZWt If you'd like to learn more about our work with iPSC-derived ventricular and atrial cardiomyocytes, click here to explore our 2024 Cardiac Guide: https://lnkd.in/eWWWV_-s #lifescience #cellculture #microfluidics #OOC #organoids

📣 New publication alert!📣 We're delighted that our paper with innoVitro has been published: "Chamber-Specific Contractile Responses of Atrial and Ventricular hiPSC Cardiomyocytes to GPCR and Ion Channel Targeting Compounds: A Microphysiological System for Cardiac Drug Development". Human iPSC technology has been used to produce more human-relevant models for cardiac research and cardiotoxicity screening. But given the chamber-specific nature of certain conditions (for example, atrial fibrillation versus hypertrophic cardiomyopathy) these models must incorporate chamber types specific to the application. In collaboration with innoVitro, we sought to explore the chamber-specific pharmacology of axoCells™ atrial and ventricular cardiomyocytes on an innovative platform combining Nanion technologies' FLEXcyte 96 contractility platform with innoVitro's FLEXcyte plates. Our results demonstrated key pharmacological differences between axoCells atrial and ventricular cardiomyocytes and their application on a multi-well contractility platform to gain insights for in vitro cardiac liability studies and disease modelling. Click here to read the paper: https://hubs.la/Q02D8_z-0 #iPSCs #cardiomyocytes #CiPA #cardiotoxicity #StemCells

I’m very excited about the results from our KARDIA-2 Phase 2 study of zilebesiran, our investigational RNAi therapeutic in development for hypertension, which we shared this weekend at the American College of Cardiology Scientific Session. The unmet need in #hypertension is enormous – it’s the number one preventable cause of cardiovascular morbidity and death worldwide.   Approximately one in every three adults worldwide – at least 200 million people in just the U.S. and other major markets – is living with hypertension, and for up to 80% of these people, their blood pressure remains uncontrolled, despite the availability of numerous treatments.    As the leader in #RNAi therapeutics, Alnylam Pharmaceuticals has the potential to reinvent the treatment of cardiovascular disease and – in the case of hypertension – address one the world’s biggest healthcare challenges.    #ACC24 #RNAiTherapeutics #siRNA #cardiology

🚨 New Clinical Trial Recruitment: "Study of Cryoablation and Nirogacestat for Desmoid Tumor" Stanford University recently opened up a new clinical trial for desmoid tumors combining local treatment of cryoablation with the newly FDA approved gamma secretase inhibitor nirogacestat. The ideal candidates for this trial are patients with desmoid tumors that cannot be completely cryoablated, with a target of 50-75% of the tumor volume for cryoablation. Currently recruiting patients who have US medical insurance and are able to travel to Stanford monthly for treatment. All patients must have the MRIs evaluated by Stanford interventional radiologists to determine if they are suitable for trial enrollment. View the trial details and criteria: https://lnkd.in/e3FJqrg2 #Desmoid #clinicaltrial #DesmoidTumors #DesmoidTumor #aggressivefibromatosis #DTRF #DesmoidTumorResearchFoundation #Desmoidian #desmoidresearch

Today, we presented full results of our KARDIA-2 Phase 2 study as a late-breaking clinical trial at the American College of Cardiology Annual Scientific Session. The study evaluated zilebesiran, an investigational #RNAi therapeutic for the treatment of #hypertension, when added to standard of care antihypertensives. Learn more: https://bit.ly/43N1OSm #siRNA #ACC24

NASCI 2024 just concluded, showing how the integration of real-world data, including imaging data, is essential for driving innovation in cardiovascular research. Our fit-for-purpose regulatory grade real-world imaging datasets (RWiD) and multimodal longitudinal datasets are tailored to meet the needs of pharmaceutical and biotech companies. These datasets have been instrumental in planning and optimizing clinical trials, ensuring the recruitment of suitable patients. Reach out to us at https://hubs.li/Q02RhfXy0 to know more about how our data sets and solutions have supported identification of suitable patient cohorts for treatment and streamline clinical trial planning. Let’s connect to discover how we can support your next big breakthrough in cardiology. #CardiovascularResearch #MedicalImaging #PharmaExcellence #NASCI2024 #Cardiology #Radiology #RWD #RWiD #RWE